New TECOS analysis adds heart failure data for sitagliptin

(European Society of Cardiology) Patients with type-2 diabetes and cardiovascular disease can safely take the antihyperglycemic drug sitagliptin without an increased risk of cardiovascular complications -- even if they have a history of heart failure -- a new analysis of the TECOS (Trial Evaluating Cardiovascular Outcomes with Sitagliptin) study shows.